CA2261887A1 - Covalent polar lipid conjugates with biologically-active compounds for use in salves - Google Patents

Covalent polar lipid conjugates with biologically-active compounds for use in salves

Info

Publication number
CA2261887A1
CA2261887A1 CA002261887A CA2261887A CA2261887A1 CA 2261887 A1 CA2261887 A1 CA 2261887A1 CA 002261887 A CA002261887 A CA 002261887A CA 2261887 A CA2261887 A CA 2261887A CA 2261887 A1 CA2261887 A1 CA 2261887A1
Authority
CA
Canada
Prior art keywords
salves
drug
drugs
agents
targeting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002261887A
Other languages
French (fr)
Other versions
CA2261887C (en
Inventor
Milton B. Yatvin
Michael H. B. Stowell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon Health Science University
Original Assignee
Oregon Health Sciences University
Milton B. Yatvin
Michael H. B. Stowell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health Sciences University, Milton B. Yatvin, Michael H. B. Stowell filed Critical Oregon Health Sciences University
Publication of CA2261887A1 publication Critical patent/CA2261887A1/en
Application granted granted Critical
Publication of CA2261887C publication Critical patent/CA2261887C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Abstract

This invention herein describes a method of facilitating the entry of drugs into cells and tissues at pharmokinetically useful levels and also a method of targeting drugs to specific organelles within the cell.
This polar lipid/drug conjugate targeting invention embodies an advance over other drug targeting methods because through this method, intracellular drug concentrations may reach levels which are orders of magnitude higher than those achieved otherwise. Furthermore, it refines the drug delivery process by allowing therapeutic agents to be directed to certain intracellular structures. This technology is appropriate for use with antiproliferative, antibiotic, antimycotic, antiviral and antineoplastic drugs, in particular in combination with a multiplicity of other emollients and agents to make up topically-active substances such as salves, for rapid and efficient introduction of such agents through the epidermis for treatment of skin diseases and other disorders.
CA002261887A 1996-07-23 1996-07-23 Covalent polar lipid conjugates with biologically-active compounds for use in salves Expired - Fee Related CA2261887C (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1996/012124 WO1998003204A1 (en) 1996-07-23 1996-07-23 Covalent polar lipid conjugates with biologically-active compounds for use in salves

Publications (2)

Publication Number Publication Date
CA2261887A1 true CA2261887A1 (en) 1998-01-29
CA2261887C CA2261887C (en) 2007-10-02

Family

ID=22255500

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002261887A Expired - Fee Related CA2261887C (en) 1996-07-23 1996-07-23 Covalent polar lipid conjugates with biologically-active compounds for use in salves

Country Status (5)

Country Link
EP (1) EP0917473A1 (en)
JP (1) JPH11514009A (en)
AU (1) AU724421B2 (en)
CA (1) CA2261887C (en)
WO (1) WO1998003204A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000033883A1 (en) * 1998-12-04 2000-06-15 Oregon Health Sciences University Covalent polar lipid conjugates with antimicrobial and antineoplastic drugs for targeting to biological protected sites
US6464992B2 (en) * 2000-04-14 2002-10-15 University Of Kentucky Research Foundation Topical micronutrient delivery system and uses thereof
US7045543B2 (en) 2001-11-05 2006-05-16 Enzrel Inc. Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
CN103857440B (en) * 2011-06-22 2018-09-25 维奥姆生物科学有限公司 Antimycotic and antibacterium prodrug based on conjugate
WO2024083171A1 (en) * 2022-10-20 2024-04-25 苏州艾博生物科技有限公司 Lipid compound and lipid nanoparticle composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
DE69119074T2 (en) * 1990-06-15 1996-12-12 Univ Wake Forest COVALENT THER LIPID NUCLEOSIDE CONJUGATES
US5149794A (en) * 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
US5256641A (en) * 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting

Also Published As

Publication number Publication date
CA2261887C (en) 2007-10-02
JPH11514009A (en) 1999-11-30
EP0917473A1 (en) 1999-05-26
AU6594596A (en) 1998-02-10
AU724421B2 (en) 2000-09-21
WO1998003204A1 (en) 1998-01-29

Similar Documents

Publication Publication Date Title
CA2269947A1 (en) Covalent polar lipid conjugates for targeting
US5543389A (en) Covalent polar lipid-peptide conjugates for use in salves
DE60026538D1 (en) PHARMACEUTICAL PREPARATIONS THE CLAVULANIC ACID OR DERIVATIVES CONTAIN FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
WO2003039677A3 (en) Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
MY124853A (en) 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives.
CA2079814A1 (en) Cationic lipids for intracellular delivery of biologically active molecules
WO2002043652A3 (en) Anti-proliferative drugs
CA2184242A1 (en) Drug Targeting System, Method for Preparing Same and Its Use
WO2004060384A3 (en) Pharmaceutical botulinum toxin compositions
WO2006086631A3 (en) Methods for implementing microbeam radiation therapy
WO2005084710A3 (en) Nanocell drug delivery system
RU93058654A (en) METHOD FOR DETERMINING THE USEFULNESS OF CURRENT LIVING COOKIES, THEIR APPLICATION IN THERAPY, MEDICINE
EP2186902A3 (en) Medical preparations for the treatment of alpha-galactosidase a deficiency
EP0858996A4 (en) Nerve cell protective agents
WO2006068759A3 (en) Liposomes containing phytochemical agents and methods for making and using same
HRP20080598T3 (en) Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer
AU2002231889A1 (en) Halogenated composition, method for preparing same and uses thereof
WO2001026704A3 (en) Targeted drug activation
WO2000018316A3 (en) Sustained release, and comfortable ophthalmic composition and method for ocular therapy
WO2003072030A3 (en) Methods for preventing or treating cardiac arrhythmia
CA2317582A1 (en) A drug dosage form based on the teorell-meyer gradient
DE69316379T2 (en) MORPHOGENIC REGENERATION OF LIVER
WO2002102311A3 (en) Nanoparticles for treating targeted tissues and cells
CA2261887A1 (en) Covalent polar lipid conjugates with biologically-active compounds for use in salves
HU229598B1 (en) Preparations for the application of anti-inflammatory agents

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed